GB0717187D0 - Compositions comprising yersinia pestis antigens - Google Patents

Compositions comprising yersinia pestis antigens

Info

Publication number
GB0717187D0
GB0717187D0 GBGB0717187.9A GB0717187A GB0717187D0 GB 0717187 D0 GB0717187 D0 GB 0717187D0 GB 0717187 A GB0717187 A GB 0717187A GB 0717187 D0 GB0717187 D0 GB 0717187D0
Authority
GB
United Kingdom
Prior art keywords
compositions
yersinia pestis
pestis antigens
antigens
yersinia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0717187.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0717187.9A priority Critical patent/GB0717187D0/en
Publication of GB0717187D0 publication Critical patent/GB0717187D0/en
Priority to AU2008294413A priority patent/AU2008294413A1/en
Priority to EP08829437A priority patent/EP2205274A2/en
Priority to JP2010523608A priority patent/JP2012501959A/ja
Priority to CA2698360A priority patent/CA2698360A1/en
Priority to PCT/IB2008/003081 priority patent/WO2009031043A2/en
Priority to US12/733,488 priority patent/US20100183674A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
GBGB0717187.9A 2007-09-04 2007-09-04 Compositions comprising yersinia pestis antigens Ceased GB0717187D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB0717187.9A GB0717187D0 (en) 2007-09-04 2007-09-04 Compositions comprising yersinia pestis antigens
AU2008294413A AU2008294413A1 (en) 2007-09-04 2008-09-04 Compositions comprising Yersinia pestis antigens
EP08829437A EP2205274A2 (en) 2007-09-04 2008-09-04 Compositions comprising yersinia pestis antigens
JP2010523608A JP2012501959A (ja) 2007-09-04 2008-09-04 Ｙｅｒｓｉｎｉａｐｅｓｔｉｓ抗原を含む組成物
CA2698360A CA2698360A1 (en) 2007-09-04 2008-09-04 Compositions comprising yersinia pestis antigens
PCT/IB2008/003081 WO2009031043A2 (en) 2007-09-04 2008-09-04 Compositions comprising yersinia pestis antigens
US12/733,488 US20100183674A1 (en) 2007-09-04 2008-09-04 Compositions comprising yersinia pestis antigens

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0717187.9A GB0717187D0 (en) 2007-09-04 2007-09-04 Compositions comprising yersinia pestis antigens

Publications (1)

Publication Number Publication Date
GB0717187D0 true GB0717187D0 (en) 2007-10-17

Family

ID=38640215

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0717187.9A Ceased GB0717187D0 (en) 2007-09-04 2007-09-04 Compositions comprising yersinia pestis antigens

Country Status (7)

Country Link
US (1) US20100183674A1 (https=)
EP (1) EP2205274A2 (https=)
JP (1) JP2012501959A (https=)
AU (1) AU2008294413A1 (https=)
CA (1) CA2698360A1 (https=)
GB (1) GB0717187D0 (https=)
WO (1) WO2009031043A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
HUE026646T2 (en) 2010-07-06 2016-07-28 Glaxosmithkline Biologicals Sa Preferred liposomes containing lipids of PKA value for delivery of RNA
PL2591114T3 (pl) 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunizacja dużych ssaków małymi dawkami rna
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
RS63817B1 (sr) 2010-07-06 2023-01-31 Glaxosmithkline Biologicals Sa Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
PT3970742T (pt) 2010-08-31 2022-06-27 Glaxosmithkline Biologicals Sa Lipossomas peguilados para entrega de arn codificador de imunogénio
ES2727583T3 (es) 2010-08-31 2019-10-17 Glaxosmithkline Biologicals Sa Lípidos adecuados para la administración liposómica de ARN que codifica proteínas
JP2013544504A (ja) 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
WO2012129483A1 (en) 2011-03-24 2012-09-27 Novartis Ag Adjuvant nanoemulsions with phospholipids
US20140141070A1 (en) 2011-07-06 2014-05-22 Andrew Geall Liposomes having useful n:p ratio for delivery of rna molecules
WO2013006838A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
EP3508220A1 (en) 2011-08-31 2019-07-10 GlaxoSmithKline Biologicals S.A. Pegylated liposomes for delivery of immunogen-encoding rna
US9764027B2 (en) 2012-09-18 2017-09-19 Glaxosmithkline Biologicals Sa Outer membrane vesicles
EP3608308B1 (en) 2013-03-08 2021-07-21 Novartis AG Lipids and lipid compositions for the delivery of active agents
ES2895651T3 (es) 2013-12-19 2022-02-22 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
EP4019506A1 (en) 2013-12-19 2022-06-29 Novartis AG Lipids and lipid compositions for the delivery of active agents
EP3169309B1 (en) 2014-07-16 2023-05-10 Novartis AG Method of encapsulating a nucleic acid in a lipid nanoparticle host
US10125092B2 (en) 2014-09-05 2018-11-13 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
JP2023546175A (ja) 2020-10-14 2023-11-01 ジョージ・メイソン・リサーチ・ファウンデーション・インコーポレイテッド 脂質ナノ粒子製造の方法及びそれに由来する組成物
WO2023021421A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
WO2023021427A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
GB202303019D0 (en) 2023-03-01 2023-04-12 Glaxosmithkline Biologicals Sa Method of lyophilisation
GB202311382D0 (en) 2023-07-25 2023-09-06 Glaxosmithkline Biologicals Sa Lyophilised compostion
WO2026033498A1 (en) 2024-08-09 2026-02-12 Genvax Technologies, Inc. Methods of self-amplifying rna-lipid nanoparticle manufacture and compositions derived therefrom

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2215203C (en) * 1995-03-13 2008-12-09 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Vaccines for plague
CA2627302A1 (en) * 2005-10-25 2007-05-03 Novartis Vaccines And Diagnostics S.R.L. Compositions comprising yersinia pestis antigens

Also Published As

Publication number Publication date
JP2012501959A (ja) 2012-01-26
EP2205274A2 (en) 2010-07-14
US20100183674A1 (en) 2010-07-22
WO2009031043A3 (en) 2009-08-13
WO2009031043A2 (en) 2009-03-12
CA2698360A1 (en) 2009-03-12
AU2008294413A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
GB0717187D0 (en) Compositions comprising yersinia pestis antigens
GB0714963D0 (en) Compositions comprising antigens
IL202648A0 (en) Antibody formulations
IL247741A0 (en) pharmaceutical preparations
IL202950A0 (en) Antibody formulations
EP2173163A4 (en) ANTIBODY FORMULATIONS
GB0711656D0 (en) Formulations
GB0716385D0 (en) Formulations
GB0712884D0 (en) Formulations
EP2222313A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0809979D0 (en) Formulations
GB0711957D0 (en) Formulations
GB0707127D0 (en) Pharmaceutical compositions
EP2146695A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0709811D0 (en) Pharmaceutical compositions
GB0700135D0 (en) Vaccine
GB0712454D0 (en) Pharmaceutical compositions
GB0710574D0 (en) Antifouling composition
EP2167635A4 (en) ANTIBODY FORMULATIONS
GB0705179D0 (en) Formulations
GB2454923B (en) Pharmaceutical compositions
IL201394A0 (en) Niacin - based pharmaceutical compositions
GB0702363D0 (en) Vaccine composition
GB0723900D0 (en) Lyophillised antigen composition
GB0723044D0 (en) Lyophillised antigen composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)